Homology Medicines, Inc. Contracts & Agreements
56 Contracts & Agreements
- Business Finance (13 contracts)
- Business Formation (1)
- Business Operations (7)
- Human Resources (20)
- Intellectual Property (5)
- Real Estate (3)
- Uncategorized (7)
- Non-Employee Director Compensation Program (Filed With SEC on November 10, 2022)
- Amendment to Employment Agreement, dated as of September 6, 2022, between Homology Medicines, Inc. and Paul G. Alloway, Ph.D (Filed With SEC on November 10, 2022)
- Amendment to Employment Agreement, dated as of September 6, 2022, between Homology Medicines, Inc. and Michael Blum (Filed With SEC on November 10, 2022)
- Consulting Agreement, dated as of September 6, 2022, between Homology Medicines, Inc. and Arthur O. Tzianabos, Ph.D (Filed With SEC on September 8, 2022)
- Amendment to Employment Agreement, dated as of September 6, 2022, between Homology Medicines, Inc. and W. Bradford Smith (Filed With SEC on September 8, 2022)
- Amended and Restated Employment Agreement, dated as of April 21, 2022, between Homology Medicines, Inc. and Albert Seymour, Ph.D (Filed With SEC on April 21, 2022)
- Assignment and Assumption Agreement, dated March 10, 2022, between Homology Medicines, Inc. and Roadrunner Solutions LLC (Filed With SEC on March 23, 2022)
- Sublease Agreement, dated March 10, 2022, between Homology Medicines, Inc. and Roadrunner Solutions LLC (Filed With SEC on March 23, 2022)
- Employment Agreement, dated March 18 2020, by and between Homology Medicines, Inc. and Paul Alloway, Ph.D (Filed With SEC on March 23, 2022)
- Employment Agreement, dated September 1, 2021, by and between Homology Medicines, Inc. and Michael Blum (Filed With SEC on March 23, 2022)
- Equity Securities Purchase Agreement, dated January 28, 2022, by and among Homology Medicines, Inc., Roadrunner Solutions LLC, Oxford Biomedica (US), Inc. and, solely for purposes... (Filed With SEC on March 23, 2022)
- Amendment No. 1 to Equity Securities Purchase Agreement dated as of January 28, 2022 by and among Homology Medicines, Inc., Roadrunner Solutions LLC, Oxford Biomedica (US), Inc.... (Filed With SEC on March 23, 2022)
- Contribution Agreement, dated March 10, 2022, between Homology Medicines, Inc. and Roadrunner Solutions LLC (Filed With SEC on March 23, 2022)
- Amended and Restated Limited Liability Company Agreement, dated March 10, 2022, by and among Oxford Biomedica Solutions LLC (f/k/a Roadrunner Solutions LLC), Homology Medicines,... (Filed With SEC on March 23, 2022)
- Manufacturing and Supply Agreement, dated March 10, 2022, by and among Homology Medicines, Inc., Roadrunner Solutions LLC and, solely for purposes of Section 2.3(b)(iii) thereof,... (Filed With SEC on March 23, 2022)
- Underwriting Agreement, dated April 6, 2021, by and between the Company and BTIG, LLC (Filed With SEC on April 9, 2021)
- Description of Securities (Filed With SEC on March 11, 2021)
- 2018 Incentive Award Plan, and forms of awards thereunder (Filed With SEC on March 11, 2021)
- Amended and Restated Investors Rights Agreement, dated July 28, 2017, by and among Homology Medicines, Inc. and the investors named therein, as amended by Amendment No. 1 Amended... (Filed With SEC on November 9, 2020)
- Second Amendment to Collaboration and License Agreement, dated October 30, 2020, between Homology Medicines, Inc. and Novartis Institutes for BioMedical Research, Inc (Filed With SEC on November 9, 2020)
- Stock Purchase Agreement, dated November 9, 2020, by and between Homology Medicines, Inc. and Pfizer Inc (Filed With SEC on November 9, 2020)
- Amendment to Collaboration and License Agreement, dated December 17, 2018, between Homology Medicines, Inc. and Novartis Institutes for BioMedical Research, Inc (Filed With SEC on August 10, 2020)
- Description of Securities (Filed With SEC on March 12, 2020)
- Non-Employee Director Compensation Program (Filed With SEC on March 12, 2020)
- Employment Agreement, November 12, 2019, by and between Homology Medicines, Inc. and Gabriel M. Cohn, M.D (Filed With SEC on March 12, 2020)
- Underwriting Agreement, dated April 9, 2019, by and among the Company and Merrill Lynch, Pierce, Fenner & Smith Incorporated and Cowen and Company, LLC, as representatives of the... (Filed With SEC on April 11, 2019)
- Employment Agreement, dated April 2, 2018, by and between Homology Medicines, Inc. and Tim Kelly (Filed With SEC on March 12, 2019)
- 2018 Employee Stock Purchase Plan Offering Document (Filed With SEC on November 13, 2018)
- Collaboration and License Agreement, dated November 6, 2017, between the Registrant and Novartis Institutes for BioMedical Research, Inc (Filed With SEC on March 23, 2018)
- Form of Underwriting Agreement (Filed With SEC on March 19, 2018)
- Specimen Stock Certificate evidencing the shares of common stock (Filed With SEC on March 19, 2018)
- 2015 Stock Incentive Plan, as amended, and form of option agreements thereunder (Filed With SEC on March 19, 2018)
- 2018 Incentive Award Plan and form of option agreements thereunder (Filed With SEC on March 19, 2018)
- 2018 Employee Stock Purchase Plan (Filed With SEC on March 19, 2018)
- Non-Employee Director Compensation Program (Filed With SEC on March 19, 2018)
- Form of Indemnification Agreement for Directors and Officers (Filed With SEC on March 19, 2018)
- Offer Letter to Arthur O. Tzianabos, dated March 31, 2016 (Filed With SEC on March 19, 2018)
- Employment Agreement, by and between the Registrant and Siyamak (Sam) Rasty (to be effective upon the closing of this offering) (Filed With SEC on March 19, 2018)
- Employment Agreement, by and between the Registrant and Albert Seymour (to be effective upon the closing of this offering) (Filed With SEC on March 19, 2018)
- Employment Agreement, by and between the Registrant and Bradford Smith (to be effective upon the closing of this offering) (Filed With SEC on March 19, 2018)
- Employment Agreement, by and between the Registrant and Arthur Tzianabos, Ph.D. (to be effective upon the closing of this offering) (Filed With SEC on March 19, 2018)
- Collaboration and License Agreement, dated November 6, 2017, between the Registrant and Novartis Institutes for BioMedical Research, Inc (Filed With SEC on March 19, 2018)
- Exclusive License Agreement, dated April 28, 2016, between the Registrant and City of Hope (Filed With SEC on March 19, 2018)
- License Agreement, dated September 14, 2016, between the Registrant and California Institute of Technology (Filed With SEC on March 19, 2018)
- Amended and Restated Investors Rights Agreement dated July 28, 2017, among the Registrant and the investors named therein (Filed With SEC on March 2, 2018)
- 2015 Stock Incentive Plan, as amended, and form of option agreements thereunder (Filed With SEC on March 2, 2018)
- Lease Agreement, dated August 31, 2016, between the Registrant and ARE-MA Region No. 24, LLC (Filed With SEC on March 2, 2018)
- Lease Agreement, dated December 21, 2017, between the Registrant and Bedford Patriots Park, LLC (Filed With SEC on March 2, 2018)
- Offer Letter to Siyamak (Sam) Rasty, dated December 7, 2015 (Filed With SEC on March 2, 2018)
- Offer Letter to Albert Seymour, dated February 14, 2016 (Filed With SEC on March 2, 2018)
- Offer Letter to Arthur O. Tzianabos, dated March 31, 2016 (Filed With SEC on March 2, 2018)
- Collaboration and License Agreement, dated November 6, 2017, between the Registrant and Novartis Institutes for BioMedical Research, Inc (Filed With SEC on March 2, 2018)
- Exclusive License Agreement, dated April 28, 2016, between the Registrant and City of Hope (Filed With SEC on March 2, 2018)
- License Agreement, dated September 14, 2016, between the Registrant and California Institute of Technology (Filed With SEC on March 2, 2018)
- First Amendment to License Agreement, dated May 16, 2017, between the Registrant and California Institute of Technology (Filed With SEC on March 2, 2018)
- Letter Agreement, dated November 14, 2017, between the Registrant and California Institute of Technology (Filed With SEC on March 2, 2018)